Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases
•Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered. A uniform treatment strategy for patients suffering fr...
Gespeichert in:
Veröffentlicht in: | Clinical colorectal cancer 2021-12, Vol.20 (4), p.e263-e272 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e272 |
---|---|
container_issue | 4 |
container_start_page | e263 |
container_title | Clinical colorectal cancer |
container_volume | 20 |
creator | Hellingman, Tessa Kuiper, Babette I. Buffart, Laurien M. Meijerink, Martijn R. Versteeg, Kathelijn S. Swijnenburg, Rutger-Jan van Delden, Otto M. Haasbeek, Cornelis J.A. de Vries, Jan J.J. van Waesberghe, Jan Hein T.M. Zonderhuis, Barbara M. van der Vliet, Hans J. Kazemier, Geert |
description | •Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered.
A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM.
Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses.
A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021).
Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM.
Repeat local treatment should be considered in patients suffering from early recurrence of colorectal cancer liver metastases (CRLM). A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment of CRLM, appeared favorable in patients with recurrence within 4 months. The optimal sequence and the role of systemic therapy in patient selection should be further clarified in prospective studies. |
doi_str_mv | 10.1016/j.clcc.2021.07.007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2567987585</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1533002821000724</els_id><sourcerecordid>2567987585</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-6c35a089d5c40230e17e10897a30a8441d5215ca52e1a4070255a86a6cd3e4e13</originalsourceid><addsrcrecordid>eNp9kE9r3DAQxUVJaf40XyCHomMudkeSZXkhl2ZJmsKWliY5C0UeFy22tZHshUA_fMdsmmNBSG-G9x7ox9iFgFKAqD9vS997X0qQogRTAph37ESsVFNAbaoj0lqpAkA2x-w05y2pWgnxgR2rqqqlFOKE_bmf0z7sXc-vccQuTDx2_Bfu0E18Ez3tHxLpAceJh5H_dFMgmfn93HWYwvib36Y48BuX-hfK-TklHD0uLevYx4R-oo61o13im7Cn-ztOLtPB_JG971yf8fz1PWOPtzcP67ti8-Prt_WXTeErgKmovdIOmlWraZYKUBgUNBunwDVVJVothfZOSxSuAgNSa9fUrvatwgqFOmOXh95dis8z5skOIXvsezdinLOVujarxuhGk1UerD7FnBN2dpfC4NKLFWAX6nZrF-p2oW7BWKJOoU-v_fPTgO1b5B9mMlwdDEi_3AdMNvuwcGrDQsi2Mfyv_y9x4JMT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2567987585</pqid></control><display><type>article</type><title>Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hellingman, Tessa ; Kuiper, Babette I. ; Buffart, Laurien M. ; Meijerink, Martijn R. ; Versteeg, Kathelijn S. ; Swijnenburg, Rutger-Jan ; van Delden, Otto M. ; Haasbeek, Cornelis J.A. ; de Vries, Jan J.J. ; van Waesberghe, Jan Hein T.M. ; Zonderhuis, Barbara M. ; van der Vliet, Hans J. ; Kazemier, Geert</creator><creatorcontrib>Hellingman, Tessa ; Kuiper, Babette I. ; Buffart, Laurien M. ; Meijerink, Martijn R. ; Versteeg, Kathelijn S. ; Swijnenburg, Rutger-Jan ; van Delden, Otto M. ; Haasbeek, Cornelis J.A. ; de Vries, Jan J.J. ; van Waesberghe, Jan Hein T.M. ; Zonderhuis, Barbara M. ; van der Vliet, Hans J. ; Kazemier, Geert</creatorcontrib><description>•Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered.
A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM.
Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses.
A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021).
Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM.
Repeat local treatment should be considered in patients suffering from early recurrence of colorectal cancer liver metastases (CRLM). A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment of CRLM, appeared favorable in patients with recurrence within 4 months. The optimal sequence and the role of systemic therapy in patient selection should be further clarified in prospective studies.</description><identifier>ISSN: 1533-0028</identifier><identifier>EISSN: 1938-0674</identifier><identifier>DOI: 10.1016/j.clcc.2021.07.007</identifier><identifier>PMID: 34462211</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Ablation ; Colorectal Neoplasms - surgery ; Hepatectomy ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - surgery ; Neoplasm Recurrence, Local - therapy ; Retrospective Studies ; Survival analysis ; Systemic therapy ; Treatment strategy</subject><ispartof>Clinical colorectal cancer, 2021-12, Vol.20 (4), p.e263-e272</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-6c35a089d5c40230e17e10897a30a8441d5215ca52e1a4070255a86a6cd3e4e13</citedby><cites>FETCH-LOGICAL-c400t-6c35a089d5c40230e17e10897a30a8441d5215ca52e1a4070255a86a6cd3e4e13</cites><orcidid>0000-0002-5322-3561 ; 0000-0002-7596-1012 ; 0000-0001-6786-4215 ; 0000-0003-3861-617X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clcc.2021.07.007$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34462211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hellingman, Tessa</creatorcontrib><creatorcontrib>Kuiper, Babette I.</creatorcontrib><creatorcontrib>Buffart, Laurien M.</creatorcontrib><creatorcontrib>Meijerink, Martijn R.</creatorcontrib><creatorcontrib>Versteeg, Kathelijn S.</creatorcontrib><creatorcontrib>Swijnenburg, Rutger-Jan</creatorcontrib><creatorcontrib>van Delden, Otto M.</creatorcontrib><creatorcontrib>Haasbeek, Cornelis J.A.</creatorcontrib><creatorcontrib>de Vries, Jan J.J.</creatorcontrib><creatorcontrib>van Waesberghe, Jan Hein T.M.</creatorcontrib><creatorcontrib>Zonderhuis, Barbara M.</creatorcontrib><creatorcontrib>van der Vliet, Hans J.</creatorcontrib><creatorcontrib>Kazemier, Geert</creatorcontrib><title>Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases</title><title>Clinical colorectal cancer</title><addtitle>Clin Colorectal Cancer</addtitle><description>•Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered.
A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM.
Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses.
A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021).
Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM.
Repeat local treatment should be considered in patients suffering from early recurrence of colorectal cancer liver metastases (CRLM). A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment of CRLM, appeared favorable in patients with recurrence within 4 months. The optimal sequence and the role of systemic therapy in patient selection should be further clarified in prospective studies.</description><subject>Ablation</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Hepatectomy</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - surgery</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Retrospective Studies</subject><subject>Survival analysis</subject><subject>Systemic therapy</subject><subject>Treatment strategy</subject><issn>1533-0028</issn><issn>1938-0674</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9r3DAQxUVJaf40XyCHomMudkeSZXkhl2ZJmsKWliY5C0UeFy22tZHshUA_fMdsmmNBSG-G9x7ox9iFgFKAqD9vS997X0qQogRTAph37ESsVFNAbaoj0lqpAkA2x-w05y2pWgnxgR2rqqqlFOKE_bmf0z7sXc-vccQuTDx2_Bfu0E18Ez3tHxLpAceJh5H_dFMgmfn93HWYwvib36Y48BuX-hfK-TklHD0uLevYx4R-oo61o13im7Cn-ztOLtPB_JG971yf8fz1PWOPtzcP67ti8-Prt_WXTeErgKmovdIOmlWraZYKUBgUNBunwDVVJVothfZOSxSuAgNSa9fUrvatwgqFOmOXh95dis8z5skOIXvsezdinLOVujarxuhGk1UerD7FnBN2dpfC4NKLFWAX6nZrF-p2oW7BWKJOoU-v_fPTgO1b5B9mMlwdDEi_3AdMNvuwcGrDQsi2Mfyv_y9x4JMT</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Hellingman, Tessa</creator><creator>Kuiper, Babette I.</creator><creator>Buffart, Laurien M.</creator><creator>Meijerink, Martijn R.</creator><creator>Versteeg, Kathelijn S.</creator><creator>Swijnenburg, Rutger-Jan</creator><creator>van Delden, Otto M.</creator><creator>Haasbeek, Cornelis J.A.</creator><creator>de Vries, Jan J.J.</creator><creator>van Waesberghe, Jan Hein T.M.</creator><creator>Zonderhuis, Barbara M.</creator><creator>van der Vliet, Hans J.</creator><creator>Kazemier, Geert</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5322-3561</orcidid><orcidid>https://orcid.org/0000-0002-7596-1012</orcidid><orcidid>https://orcid.org/0000-0001-6786-4215</orcidid><orcidid>https://orcid.org/0000-0003-3861-617X</orcidid></search><sort><creationdate>202112</creationdate><title>Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases</title><author>Hellingman, Tessa ; Kuiper, Babette I. ; Buffart, Laurien M. ; Meijerink, Martijn R. ; Versteeg, Kathelijn S. ; Swijnenburg, Rutger-Jan ; van Delden, Otto M. ; Haasbeek, Cornelis J.A. ; de Vries, Jan J.J. ; van Waesberghe, Jan Hein T.M. ; Zonderhuis, Barbara M. ; van der Vliet, Hans J. ; Kazemier, Geert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-6c35a089d5c40230e17e10897a30a8441d5215ca52e1a4070255a86a6cd3e4e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Ablation</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Hepatectomy</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - surgery</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Retrospective Studies</topic><topic>Survival analysis</topic><topic>Systemic therapy</topic><topic>Treatment strategy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hellingman, Tessa</creatorcontrib><creatorcontrib>Kuiper, Babette I.</creatorcontrib><creatorcontrib>Buffart, Laurien M.</creatorcontrib><creatorcontrib>Meijerink, Martijn R.</creatorcontrib><creatorcontrib>Versteeg, Kathelijn S.</creatorcontrib><creatorcontrib>Swijnenburg, Rutger-Jan</creatorcontrib><creatorcontrib>van Delden, Otto M.</creatorcontrib><creatorcontrib>Haasbeek, Cornelis J.A.</creatorcontrib><creatorcontrib>de Vries, Jan J.J.</creatorcontrib><creatorcontrib>van Waesberghe, Jan Hein T.M.</creatorcontrib><creatorcontrib>Zonderhuis, Barbara M.</creatorcontrib><creatorcontrib>van der Vliet, Hans J.</creatorcontrib><creatorcontrib>Kazemier, Geert</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical colorectal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hellingman, Tessa</au><au>Kuiper, Babette I.</au><au>Buffart, Laurien M.</au><au>Meijerink, Martijn R.</au><au>Versteeg, Kathelijn S.</au><au>Swijnenburg, Rutger-Jan</au><au>van Delden, Otto M.</au><au>Haasbeek, Cornelis J.A.</au><au>de Vries, Jan J.J.</au><au>van Waesberghe, Jan Hein T.M.</au><au>Zonderhuis, Barbara M.</au><au>van der Vliet, Hans J.</au><au>Kazemier, Geert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases</atitle><jtitle>Clinical colorectal cancer</jtitle><addtitle>Clin Colorectal Cancer</addtitle><date>2021-12</date><risdate>2021</risdate><volume>20</volume><issue>4</issue><spage>e263</spage><epage>e272</epage><pages>e263-e272</pages><issn>1533-0028</issn><eissn>1938-0674</eissn><abstract>•Repeat local treatment is advocated in patients with early recurrence of CRLM.•Patients with very early recurrence of CRLM may benefit from a multimodality approach.•Eligibility for repeat local treatment strategies should always be considered.
A uniform treatment strategy for patients suffering from early recurrence after local treatment of CRLM is currently lacking. The aim of this observational cohort study was to assess the potential survival benefit of repeat local treatment compared to systemic therapy in patients suffering from early recurrence of CRLM.
Patients who developed recurrent CRLM within 12 months after initial local treatment with curative intent were retrospectively identified in Amsterdam University Medical Centers between 2009-2019. Differences in overall and progression-free survival among treatment strategies were assessed using multivariable Cox regression analyses.
A total of 135 patients were included. Median overall survival of 41 months [range 4-135] was observed in patients who received repeat local treatment, consisting of upfront or repeat local treatment after neoadjuvant systemic therapy, compared to 24 months [range 1-55] in patients subjected to systemic therapy alone (adjusted HR = 0.42 [95%-CI: 0.25-0.72]; P = .002). Prolonged progression-free survival was observed after neoadjuvant systemic therapy followed by repeat local treatment, as compared to upfront repeat local treatment in patients with recurrent CRLM within 4 months following initial local treatment of CRLM (adjusted HR = 0.36 [95%-CI: 0.15-0.86]; P = .021).
Patients with early recurrence of CRLM should be considered for repeat local treatment strategies. A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment, appeared favorable in patients with recurrence within 4 months following initial local treatment of CRLM.
Repeat local treatment should be considered in patients suffering from early recurrence of colorectal cancer liver metastases (CRLM). A multimodality approach, consisting of neoadjuvant systemic therapy followed by repeat local treatment of CRLM, appeared favorable in patients with recurrence within 4 months. The optimal sequence and the role of systemic therapy in patient selection should be further clarified in prospective studies.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34462211</pmid><doi>10.1016/j.clcc.2021.07.007</doi><orcidid>https://orcid.org/0000-0002-5322-3561</orcidid><orcidid>https://orcid.org/0000-0002-7596-1012</orcidid><orcidid>https://orcid.org/0000-0001-6786-4215</orcidid><orcidid>https://orcid.org/0000-0003-3861-617X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1533-0028 |
ispartof | Clinical colorectal cancer, 2021-12, Vol.20 (4), p.e263-e272 |
issn | 1533-0028 1938-0674 |
language | eng |
recordid | cdi_proquest_miscellaneous_2567987585 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Ablation Colorectal Neoplasms - surgery Hepatectomy Humans Liver Neoplasms - drug therapy Liver Neoplasms - surgery Neoplasm Recurrence, Local - therapy Retrospective Studies Survival analysis Systemic therapy Treatment strategy |
title | Survival Benefit of Repeat Local Treatment in Patients Suffering From Early Recurrence of Colorectal Cancer Liver Metastases |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T05%3A32%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Benefit%20of%20Repeat%20Local%20Treatment%20in%20Patients%20Suffering%20From%20Early%20Recurrence%20of%20Colorectal%20Cancer%20Liver%20Metastases&rft.jtitle=Clinical%20colorectal%20cancer&rft.au=Hellingman,%20Tessa&rft.date=2021-12&rft.volume=20&rft.issue=4&rft.spage=e263&rft.epage=e272&rft.pages=e263-e272&rft.issn=1533-0028&rft.eissn=1938-0674&rft_id=info:doi/10.1016/j.clcc.2021.07.007&rft_dat=%3Cproquest_cross%3E2567987585%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2567987585&rft_id=info:pmid/34462211&rft_els_id=S1533002821000724&rfr_iscdi=true |